🇺🇸 FDA
Patent

US 11197821

Formulations for treatment of dry eye disease

granted A61KA61K31/47A61K47/40

Quick answer

US patent 11197821 (Formulations for treatment of dry eye disease) held by Aldeyra Therapeutics, Inc. expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aldeyra Therapeutics, Inc.
Grant date
Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K31/47, A61K47/40, A61K9/0048, A61K9/08